Jeannine A. Villella, DO
Associate Director, Division of Gynecologic Oncology
Academic Faculty Appointments
Assistant Professor, SUNY at Stony Brook School of Medicine
Department of Obstetrics & Gynecology, 259 First Street, NP-LL, Mineola, NY 11501
Jessica Vandenberg, Administrative Assistant 516-663-2018
Dr. Jeannine Villella obtained her medical degree from New York College of Osteopathic Medicine in Old Westbury, New York and completed her residency training in Obstetrics and Gynecology at Winthrop University Hospital. Thereafter, Dr. Villella was granted a 2-year Henrietta Milstein Fellowship at Columbia University College of Physicians & Surgeons. As part of the division of gynecologic oncology, she performed research in the role of angiogenesis in ovarian cancer, and was involved in the care of gynecologic oncology patients. She then completed a 3-year subspecialty fellowship in Gynecologic Oncology at Roswell Park Cancer Institute, where she expanded her research interests into immune response to malignancy and cancer immunotherapy. She has been granted a Winthrop University Hospital Pilot Grant to pursue her research interests in genetic polymorphisms in indoleamine 2, 3- dioxygenase and the effect on ovarian cancer outcomes. Her future goals include having ovarian cancer vaccine clinical trials available at Winthrop University Hospital. She also serves on the Society of Gynecologic Oncologists Clinical Practice Committee and the Gynecologic Oncology Group Vaccine Committee. Dr. Villella is is board certified in Obstetrics & Gynecology and Gynecologic Oncology. She currently holds the title Associate Director of Gynecologic Oncology at Winthrop University Hosptital and Assistant Professor of Stony Brook School of Medicine. She is the Principle Investigator for the Gynecologic Oncology Group Clinical Trials at Winthrop University Hospital. She also serves on the Society of Gynecologic Oncologists Clinical Practice Committee. She is also an active member of the research organization Society of Gynecologic Investigation.
Description of Research Interests/Activities
Dr. VIllella's research interests are in immune response to malignancy, mechanisms of how tumors evade the immune response, and cancer immunotherapy. Her goal as a physician scientist is to bridge the divide between the laboratory and the clinic, translating basic discoveries into new therapiesÑand new hopeÑfor gynecologic cancer patients.
Areas of Experience
Immunology Tumor Vaccine Therapy Gynecologic Oncology Group Clinical Trials
Research Team Members
The Gynecologic Oncology Division clinical and research staff includes Eva Chalas, MD, Jeannine Villella, DO, Kent Chan, MD, Eddie Jimenez, DO, Jessica Gahers, PA, Jean Farrell, RN, Eleanor Colbert, RN, Cindy Pederson-Goetz, RN, Linda Milana, RN and Kristine Prazak, PA. Dr. Villella has translational and basic science collaboration with Louis Ragolia, Ph.D. Additionally, she has additional translational research collaborations with Cold Spring Harbor Laboratories and The Center for Immunotherapy at Roswell Park Cancer Institute.
Clinical Practice and Interests
Dr. Villella is a Board Certified Gynecologic Oncologist at Winthrop University Hosptial where she provides specialized care and treatment for women with all gynecologic malignancies, and complex gynecologic surgery. Her surgical approaches include robotic and minimally invasive surgery. This comprehensive care includes consultation, surgery, administration of chemotherapy and end- of-life care. She is dedicated to education, and is very involved in the education of residents and medical students. She also serves as a research mentor for residents and students. She has been invited to speak about gynecologic cancers in medical schools, at physician conferences and in the community. Dr. Villella's interest in research has been long standing, and is an integral part of her career. Her current work is in the field of immune response to malignancy; namely ovarian cancer. She is specifically interested in how cancer evades immune response and how this mechanism can be overcome to improve effect of ovarian cancer immunotherapy.
Tchabo NE, Mhawech-Fauceglia P, Caballero OL, Villella J, Beck AF, Miliotto A, Liao J, Andrews C, Lele S, Old LJ, Odunsi K. “Expression and Serum Immunoreactivity of Developmentally Restricted Differentiation Antigens in Epithelial Ovarian Cancer.” Cancer Immunity, (26 August 2009). Vol.9, p.6-12.
Qian F, Villella J, Wallace P, Mhawech-Fauceglia P, Andrews C, Valmori D, Ayoub M, Fredrick PJ, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K. “Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.” Cancer Res. 2009 Jul 1;69(13):5498-504. Epub 2009 Jun 2.
Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman E, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. “Vaccination with an NY-ESO-1 peptide of dual HLA class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses in ovarian cancer patients.” PNAS, July 31 2007, 104(31):12837-42.
Villella JA, Kaul S, Mhawech-Fauceglia P, Driscoll D, Odunsi K, Lele S. “Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary.” Int J of Gyn Pathology, 26(2):154-9, May 2007.
Villella JA, Cohen S, Tiersten A, Smith D, Hibshoosh H, Hershman D. “Her2/neu Over Expression in Uterine Papillary Serous Cancers and its Possible Therapeutic Implications.” Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-902.
Villella JA, Odunsi K, Lele S. “Review Article: The role of IDO in immune system evasion of malignancy: Another piece to the tolerance puzzle.” Cancer Therapy, 2006; 4 27-34.
Villella JA, Parmar M, Donohue K, Piver MS, Rodabaugh KJ. “Role of Hysterectomy in Patients at High Risk for Hereditary Cancers.” Gynecol Oncl. 2006;102: 475-9.
Villella J, Pauli S, Wang J, Smith D, Intengan M, Lele S. “Tumor of Low Malignant Potential Arising in the Fallopian Tube.” Eur J Gynaecol Oncol, 2005 26(3):327-9
Villella J, Chalas, E. “Optimising treatment of elderly patients with ovarian cancer: Improving their enrolment in clinical trials.” Drugs Aging. 2005; 22(2):95-100.
Villella JA, Marchetti, D, Odunsi K, Rodabaugh K, Driscoll DL, Lele S. “Response to Platinum-based agent and Gemcitabine Combination Chemotherapy in Recurrent Ovarian Cancer.” Gynecol Oncol, 2004 Dec;95(3):539-45.
Levine D, Villella J, Soslow R, Poynor E. “Gastrointestinal Adenocarcinoma Arising in a Mature Cystic Teratoma of the Ovary.” Gynecol Oncol, Aug 2004; 94(2): 597-9.
Narayan G, Arias-Pulido H, Nandula S, Sugirtharaj D, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Dürst M, Pothuri B, Murty V. “Promoter Hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA Pathway in Cervical Cancer.” Cancer Res 64:9; 2994-7, May 2004.
Narayan G, Arias-Pulido A, Koul S, Vargas H, Zhang F, Villella J, Schneider A, Terry M, Mansukhani M, Murty V, “Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome.” Mol Cancer 2003, 2:24.
Pearl M, Villella J, Valea F, DiSilvestro P, Chalas, E. “Outcomes of Surgery for Endometrial Cancer Patients with Gynecologic Oncology Involvement.” Obstet Gynecol, 2002 Oct;100(4): 724-9.
Villella JA, Chaudhry T, Pearl M, Valea F, DiSilvestro P, Pollack S, Chalas E. “Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer.” Gynecol Oncol, 2002 Sept;86 316-22.